Trevor Hallam's Biography

Trevor Hallam, Chief Scientific Officer, Sutro Biopharma Inc

Dr. Trevor Hallam has more than 25 years of experience in pharmaceutical discovery and development. He joined Sutro Biopharma as CSO in late 2010. Since then Dr. Hallam has shaped Sutro's biochemical synthesis technology to generate a disruptive discovery and manufacturing platform for novel best-in-class bispecific and antibody-drug conjugate protein therapeutics. Prior to Sutro he was Executive Vice President of Research & Development and Executive Officer at Palatin Technologies where he was responsible for Discovery, Preclinical and Clinical Development and led the discovery, IND filings and early clinical development of several drug candidates in a variety of therapeutic areas. Dr. Hallam held several senior management positions at AstraZeneca, most recently Vice President Biologics, Vice President U.S. Medical Affairs, and Vice President, Research and Pre-clinical Development, Respiratory and Inflammation, Sweden. He began his pharmaceutical career in the UK working for Smith Kline & French followed by senior management positions at Glaxo and Roche. Dr. Hallam conducted his post-doctoral training in the laboratory of Timothy Rink MD DSc at the Physiological Laboratory, University of Cambridge after receiving his Ph.D. in Biochemistry from King's College, University of London.